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Abstract 
 
The concurrent use of tramadol and diclofenac may increase hepatotoxic risk due to their individual hepatotoxic effects. This study 
assessed the hepatotoxic effect of tramadol-diclofenac administration in albino rats. Twenty-four adult male albino rats (200-220g) 
randomized into four groups were orally administered with tramadol (12mg/kg/day), diclofenac (6mg/kg/day) and tramadol-diclofenac for 
14 days respectively. The rats were anesthetized, blood samples were collected and evaluated for serum liver function and lipid 
parameters. Liver samples were weighed and evaluated for biochemical parameters and histology. The effects of tramadol-diclofenac on 
the body and liver weights did not differ significantly (p>0.05) when compared to control. Also, effects were not significant (p>0.05) on 
blood glucose, and serum cholesterol, triglyceride, low and high density lipoprotein cholesterol levels when compared to control. Liver 
and serum levels of aminotransferases, alkaline phosphatase, lactate dehydrogenase, gamma–glutamyl transferase, conjugated bilirubin 
and total bilirubin increased significantly in rats treated with tramadol (p<0.05), diclofenac (p<0.01) and tramadol-diclofenac (p<0.001) 
when compared to control. Furthermore, significant decreases in liver catalase, glutathione, superoxide dismutase, glutathione peroxidase 
levels with significant increases in malondialdehyde levels occurred in rats treated with tramadol (p<0.05), diclofenac (p<0.01) and 
tramadol-diclofenac (p<0.001) when compared to control. Hepatocyte necrosis was observed in rats treated with tramadol-diclofenac. 
Tramadol-diclofenac may increase hepatotoxic risk at doses used for this study. 
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INTRODUCTION 
 
Most medical conditions are associated with pain. Pain 
remains the most inadequately treated symptom due to 
different cultural, attitudinal, educational, legal, and 
system-related reasons (Connors et al., 1995). Pain has a 
multifactorial origin; hence it may be difficult to achieve 
effective pain control with a single drug. Combination 
therapy with analgesics from different groups is 
advantageous in targeting both peripheral and central 
pain pathways (Rawal et al., 2011). The World Health 
Organization (WHO) Analgesic Ladder recommends the 
combination of acetaminophen or NSAIDs with opioids 
as the second step in the treatment of pain, based on 
increasing pain severity (Blondel and Azadfard, 2013).  
Tramadol-diclofenac can be used for the treatment or 
management of chronic pain (Mitra et al., 2012). 
Diclofenac is a phenylacetic acid derivative which 
belongs to the acetic acid class of NSAIDs. It acts by 
inhibiting cellular cyclooxygenases (Cox-1 and Cox-2), 
which results to decreases in the production of pro-
inflammatory prostaglandin, prostacyclin and 
thromboxane products which are important mediators of 
inflammation and pain (Zimmerman, 1999; Lewis and 
Stine, 2013). Tramadol is a synthetic codeine analog that 
acts as a weak opioid agonist in addition to mildly 
inhibiting serotonin and norepinephrine reuptake. 
Tramadol is effective against mild-to-moderate pain. 
Clinically, tramadol-diclofenac use could 
advantageously target both peripheral and central pain 
pathways and leverage on the ability of individual drug 
to reduce pain and fasten recovery (Raffa, 2001). 
However, tramadol-diclofenac use may increase 
hepatotoxic risk since both drugs have hepatotoxic 
potential. Clinically, apparent liver injury due to 
diclofenac has been reported and it ranks in the top 10 
causes of drug-induced liver injury (Dunk et al., 1982). 
Tramadol can cause respiratory arrest as well as acute 
liver failure, which several fatal instances reported 
(Loughrey et al., 2003). The use of tramadol-diclofenac 
calls for hepatotoxic assessment which this study 
evaluated in a rat model.  
 
 
MATERIAL AND METHODS 
 
Animals and drugs 
Adult male albino rats of weight 200-220g were used. 
The rats were supplied by the animal house of the 
Department of Pharmacology and Toxicology Niger, 
Delta University, Nigeria. The rats were housed in four 
cages (6 per cage) and allowed to acclimatize for 2 
weeks in a well-ventilated room, maintained at a room 
temperature of 28 ± 2°C, under natural lighting 
condition. The rats were fed with standard rodents chow 
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and given water ad libitum. Tramadol hydrochloride 
(ZIM laboratories Ltd India) and diclofenac potassium 
(Adpharm Nigeria Ltd) were used for this study. All 
other chemical substances used for this study are of 
analytical grade. Higher doses of tramadol 
(12mg/kg/day) and diclofenac (6mg/kg/day) dissolved in 
normal saline were used for this study. 
 
Grouping of animals and drug treatment 
Twenty-four adult male albino rats were divided into 
four (4) groups A-D of 6 rats each. 
 Group A (control) was orally administered with 
normal saline (0.2mL) for 14 days. 
 Group B was orally administered with tramadol (12 
mg/kg/day) for 14 days. 
 Group C was orally administered with diclofenac 
(6mg/kg/day) for 14 days. 
 Group D was orally administered with tramadol 
(12mg/kg/day) and diclofenac (6mg/kg/day) for 14 
days. 
 
Collection of sample 
The rats were sacrificed with inhalational diethyl ether 
after drug administration and blood samples were 
collected from the heart. At 1500g for 15 minutes, the 
blood samples were centrifuged, serum samples 
extracted and evaluated for liver function parameters. 
Liver samples were harvested and washed in a cold 
1.15% KCl solution and homogenized in 0.1 M Tris-
HCl buffer, pH 7.4. The homogenates were centrifuged 
at 1500g for 15 minutes and the supernatants were 
decanted and evaluated for biochemical parameters. 
 
Evaluation of biochemical and oxidative stress 
indices 
Aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), 
total bilirubin (TB), conjugated bilirubin (CB), gamma-
glutamyl transferase (GGT), lactate dehydrogenase 
(LDH), total cholesterol (TC), triglyceride (TG) and 
high density lipoprotein cholesterol (HDL-C) were 
evaluated using standard laboratory test kits. Blood 
glucose (G) was evaluated using glucometer while low 
density lipoprotein cholesterol (LDL-C) was determined 
using friedewald equation. Liver protein was evaluated 
according to Gornall et al. (1949). The method described 
by Sun and Zigma, (1978) was used for the evaluation of 
superoxide dismutase (SOD) whereas catalase (CAT) 
was determined according to Aebi, (1984). Glutathione 
(GSH) was estimated as described by Sedlak and 
Lindsay, (1968) whereas glutathione peroxidase (GPx) 
was evaluated according to the method of Rotruck, et al, 
(1973). Malondialdehyde (MDA) was determined as 
reported by Buege and Aust, (1978). 
 
Histological examination of the liver 
Liver samples were fixed in 10% neutral buffered 
formalin, processed and embedded in paraffin wax. 
Sections of 5 μm thickness were cut, stained with 
haematoxylin and eosin and examined under a light 
microscope and relevant sections photographed. 
 
Statistical analysis 
Data are expressed as mean ± SEM. Data was subjected 
to student t test. Results were considered to be 
significant at p<0.05; 0.01; 0.001. 
 
 
Table 1. Effects of tramadol-diclofenac on body and liver weights of 
albino rats. 
 
Groups 
Body weight 
(g) 
Absolute liver 
weight(g) 
Relative liver 
weight (%) 
 A 
 B  
 C 
 D 
290±11.3 
295±14.2 
275±10.6 
295±11.5 
6.03±0.13 
6.22±0.25 
5.99±0.31 
6.21±0.19 
2.07±0.01 
2.10±0.73 
2.17±0.59 
2.10±0.77 
n=6. Data are expressed as mean ± SEM. 
 
 
 
Table 2. Effects of tramadol-diclofenac on blood glucose and serum lipids of albino rats. 
 
Group G(mg/dL) TG(mg/dL) TC(mg/dL) HDLC(mg/dL) LDLC(mg/dL) 
A 95.0±6.41 70.5±6.78 110.1±10.8 30.7±3.44 65.7±6.00 
B 90.7± 7.85 72.1±7.59 106.8±10.3 31.8±3.35 61.6±5.32 
C 92.0±6.42 74.9±6.70 112.0±10.6 32.6±2.61 64.5±6.42 
D 100.9±9.19 81.1±7.56 110.3±11.1 32.4±2.63 64.7±7.62 
 
n=6, Data are expressed as mean ± SEM. 
 
 
Table 3. Effects of tramadol-diclofenac on serum liver function indices of albino rats. 
 
Group AST(U/L) ALT(U/L) ALP(U/L) GGT(U/L) LDH(U/L) CB(g/dL) TB(g/dL) 
A  41.5±5.57 34.2±3.15 42.3±3.56 45.5±3.11 0.75±1.53 2.66±0.18 4.21±0.05 
B 60.5±6.96a 55.1±4.06a 69.5±6.11a 66.0±6.01a 1.60±0.71a 3.95±0.06a 6.6±0.02a 
C 89.3±6.33b 79.2±5.25b 87.7±7.71b 88.1±9.43b 2.67±0.52b 5.73±0.65b 9.8±0.06b 
D 220.6±10.7c 181.3±9.70c 211.3±9.37c 220.2±14.2c 6.21±0.37c 15.4±1.22c 22.8±0.76c 
 
n=6, Data are expressed as mean ± SEM,  a Differ significantly at p<0.05 when compared to control b Differ significantly at p<0.01 when 
compared to control, c Differ significantly at p<0.001 when compared to control. 
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Table 4. Effects of tramadol-diclofenac on liver tissue biochemical parameters of albino rats. 
 
Group AST(U/L) ALT(U/L) ALP(U/L) GGT(U/L) LDH(U/L) 
A 244.8±12.0 246.9±12.1 247.2±12.3 250.5±14.2 22.9±4.03 
B 373.8± 17.6a 374.6±20.4a 390.0±20.0a 399.0±17.4a 45.2±7.09a 
C 499.6±25.0b 470.3±26.0b 488.4±23.4b 475.1±21.2b 68.1±8.16b 
D 960.0±23.7c 983.3±41.8c 901.0±43.7c 888.2±30.6c 190.5±12.8c 
 
n=6, Data are expressed as mean ± SEM,  a Differ significantly at p<0.05 when compared to control b Differ significantly at p<0.01 when 
compared to control, c Differ significantly at p<0.001 when compared to control  
 
 
Table 5. Effect of tramadol-diclofenac on liver oxidative stress indices of albino rats. 
 
Group MDA 
(nmol/mg 
protein) 
   SOD 
(U/mg protein) 
CAT 
(U/mg protein) 
GSH 
(µmol/mg 
protein) 
   GPx 
(U/mg protein) 
A 0.17±0.06 16.2±1.89 26.4±2.77 8.96±0.15 11.7±0.16 
B 0.39± 0.04a 11.6±0.15a 17.0±0.79a 5.02±0.32a 5.25±0.01a 
C 0.52±0.04b 9.98±0.04b 13.6±1.16b 3.91±0.73b 4.00±0.18b 
D 1.37±0.32c 3.63±0.06c  5.61±0.83c 1.30±0.22c 2.57±0.82c 
 
n=6, Data are expressed as mean ± SEM, a Differ significantly at p<0.05 when compared to control b Differ significantly at p<0.01 when 
compared to control, c Differ significantly at p<0.001 when compared to control  
 
 
 
 
 
 
Figure 1. (A-E) showed the liver of control rat, rats treated with 
diclofenac, tramadol and diclofenac-tramadol (H &E stain 400x). (A): The 
liver of control rat showing normal hepatocytes (B): Liver of rat treated 
with tramadol (12 mg/kg/day) showing hepatocyte necrosis (C): Liver of 
rat treated with diclofenac (6 mg/kg/day) showing hepatocyte necrosis. 
(D): Liver of rat treated with diclofenac-tramadol showing hepatocyte 
necrosis  
 
 
RESULTS 
 
The effects of tramadol-diclofenac were not significant 
(p>0.05) on the body and liver weights of treated rats 
when compared to control (Table 1). Also, serum TC, 
TG, HDL cholesterol, LDL cholesterol and blood G 
levels were normal (p>0.05) in rats treated with 
tramadol- diclofenac when compared to control (Table 
2). Serum AST, ALP, ALT, GGT, LDH, CT and TB 
levels were significantly increased in tramadol (p<0.05) 
and diclofenac (p<0.01) treated rats when compared to 
control. However, elevations in the serum levels of the 
aforementioned parameters were most significant 
(p<0.001) in rats treated with tramadol-diclofenac when 
compared to control (Table 3). The liver levels of AST, 
ALP, ALT, GGT and LDH were significantly increased 
in rats treated with tramadol (p<0.05) and diclofenac 
(p<0.01), but significant increases occurred at p<0.001 
in rats treated with tramadol-diclofenac when compared 
to control (Table 4). Furthermore, liver SOD, CAT, 
GSH and GPx levels were significantly decreased 
whereas MDA levels were significantly increased in rats 
treated with tramadol (p<0.05), diclofenac (p<0.01) and 
tramadol-diclofenac (p<0.001) when compared to 
control (Table 5). The liver of control rat showed normal 
hepatocytes (Fig A) whereas the liver of rat treated with 
tramadol and diclofenac showed hepatocyte necroses 
respectively (Fig B and C). The liver of rats treated with 
tramadol-diclofenac also showed hepatocyte necrosis 
(Fig D). 
 
 
DISCUSSION 
 
The present study evaluated the hepatotoxic effect of 
tramadol-diclofenac in a rat model. The indices 
evaluated in this study are useful parameters to indicate 
impairment in the functional capacity of the liver. 
Analysis of organ weight in toxicology studies is an 
important endpoint for the identification of potentially 
harmful effects of chemicals. It is one of the most 
sensitive drug toxicity indicators, and its changes often 
precede morphological changes (Bailey et al., 2004). In 
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the present study, tramadol-diclofenac had no effects on 
the body and liver weights of treated rats. Serum ALP, 
AST, ALT, GGT, and LDH are excellent biomarkers of 
hepatocellular injury. AST and ALT participate in 
gluconeogenesis by catalyzing the transfer of amino 
groups from aspartic acid or alanine to ketoglutaric acid 
to produce oxaloacetic acid and pyruvic acid 
respectively. AST is present in cytosolic and 
mitochondrial isoenzymes and is found in the liver while 
ALT, a cytosolic enzyme is found in its highest 
concentration in the liver and is more specific to the 
liver. ALP is found histochemically in the microvilli of 
bile canaliculi and on the sinusoidal surface of 
hepatocytes (Rosalki and Mcintyre, 1999). GGT is a 
microsomal enzyme that is abundant in hepatocytes and 
biliary epithelial cells. It is involved in the transfer of γ-
glutamyl groups from peptides to amino acids and the 
metabolism of glutathione conjugates (Friedman et al., 
1996). These liver biomarkers are usually released into 
circulation causing elevated serum levels with the 
advent of hepatocellular injury (Yousef et al., 2010). 
This study observed elevated serum and liver levels of 
ALP, AST, ALT, GGT, and LDH in rats treated with 
tramadol-diclofenac which is a sign of hepatotoxicity. 
Bilirubin is an endogenous anion derived from the 
regular degradation of haemoglobin from the red blood 
cells and excreted from the liver in the bile (Saukkonen 
et al., 2006). Toxic insult to the liver can impair its 
excretory capacity to dispose bilirubin stimulating serum 
accumulation (Gaw et al., 1999; Jain et al., 2008). This 
study observed elevated serum CB and TB levels in rats 
treated with tramadol-diclofenac. 
The anti-oxidative defense system which includes 
SOD, CAT, GSH and GPx is necessary for the 
maintenance of redox homeostasis in organisms. It 
terminates or prevents free radicals such as reactive 
oxygen species (ROS) from incapacitating the functions 
of biomolecules through oxidative stress (OS) (Borković 
et al., 2005). However, the functions of anti-oxidative 
system can be surmounted or incapacitated via depletion 
by over whelming actions of free radicals. This study 
observed hepatic depletions of SOD, CAT, GSH and 
GPx in rats treated with tramadol-diclofenac. This is an 
evidence which shows that OS is a factor in 
hepatotoxicity induced by tramadol-diclofenac. Lipid 
peroxidation (LPO) is an oxidative degradation of 
polyunsaturated fatty acids which can cause impairment 
in membrane structure and function. MDA level which 
is an important indicator of LPO can indirectly reflect 
the extent of hepatic LPO in-vivo and in-vitro (Jafari et 
al., 2012). In this study, hepatic MDA levels were 
increased in rats treated with tramadol-diclofenac. This 
observation attests to the involvement of LPO in 
hepatotoxicity induced by tramadol-diclofenac. 
Furthermore, the current study observed hepatocyte 
necrosis in rats treated with tramadol-diclofenac which 
correlates with changes observed in evaluated 
biochemical parameters. This study was able to show 
that tramadol-diclofenac use may increase the risk of 
hepatotoxicity. The use of diclofenac has been 
associated with hepatotoxicity (Hussein et al., 2016) and 
hepatic OS (Das and Roy, 2012) which is consistent 
with findings in this study. The exact mechanism by 
which diclofenac causes hepatotoxicity is not well 
understood, but diclofenac is metabolized in the liver 
(Castel et al., 1997) and its hepatotoxic effect has been 
related to its metabolites (4hydroxy 3 diclofenac, 5 
hydroxy 4 diclofenac and 5 hydroxy 6 diclofenac) (Tang 
et al., 1999). Also, studies have associated tramadol 
with hepatotoxicity (El-Wessemy, 2008) characterized 
by OS (Rukhshanda et al., 2014) which is in agreement 
with observation in the present study. The mechanism 
by which tramadol causes hepatotoxicity is not fully 
known, but studies have speculated that tramadol and/or 
its active metabolite can stimulate hepatic ROS 
production leading to OS and hepatic biomolecular 
damage (Singal et al., 1998). 
 
 
CONCLUSION 
 
Tramadol-diclofenac use may be associated with 
hepatotoxicity at the doses use for this study. 
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